{"url":"https://newsforagent.com/news/2026-10-26/pfizer-talzenna-xtandi-fda-approval","markdown_url":"https://newsforagent.com/news/2026-10-26/pfizer-talzenna-xtandi-fda-approval.md","title":"Pfizer Wins FDA Approval for Earlier TALZENNA-XTANDI Use","headline":"Pfizer's TALZENNA Plus XTANDI Cleared by FDA for Earlier Metastatic Prostate Cancer","description":"Pfizer's TALZENNA plus XTANDI won FDA approval for earlier HRR-mutated metastatic prostate cancer, cutting progression or death risk by 52% in TALAPRO-3.","section":"Regulation & Approvals","published_at":"2026-10-26T18:08:07+00:00","modified_at":"2026-10-26T18:08:07+00:00","author":"News Desk","key_takeaways":["The FDA expanded approval of Pfizer's TALZENNA plus XTANDI to men with HRR gene-mutated metastatic androgen pathway modulation-naive or -sensitive prostate cancer.","The Phase 3 TALAPRO-3 study enrolled 599 patients and showed a 52% reduction in the risk of radiographic progression or death versus placebo plus XTANDI.","An application for TALZENNA plus XTANDI is under review by the European Medicines Agency, with additional global filings planned or underway."],"companies":[{"name":"Pfizer","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00000dw/pfizer","website":"http://www.pfizer.com"}],"source":{"publisher":"Business Wire","title":"Pfizer FDA approves TALZENNA-XTANDI for earlier use","url":"https://www.businesswire.com/news/home/20261020160556/en/"},"other_sources":[],"tags":["Regulation & Approvals","Pfizer"],"body_markdown":"[Pfizer](https://akta.pro/company-profiles/00000dw/pfizer) said the FDA expanded approval of TALZENNA plus XTANDI to men with HRR gene-mutated metastatic androgen pathway modulation-naive or -sensitive prostate cancer, a setting also called metastatic hormone-sensitive prostate cancer. The [Business Wire](https://www.businesswire.com/news/home/20261020160556/en/) report said the Phase 3 TALAPRO-3 trial showed the combination reduced the risk of radiographic progression or death by 52% versus placebo plus XTANDI.\n\n## What the TALAPRO-3 Trial Found\n\nThe approval covers both BRCA and non-BRCA HRR mutations, with eligibility determined by an FDA-authorized test. TALAPRO-3 enrolled 599 patients with mAPMN/S prostate cancer and up to three months of androgen deprivation therapy, with or without an approved ARPI, at sites in the U.S., Canada, Europe, South America, and the Asia-Pacific region. Patients were randomized to TALZENNA 0.5 mg/day plus XTANDI 160 mg/day, or placebo plus XTANDI 160 mg/day.\n\nThe study reported a hazard ratio of 0.48, with a 95% confidence interval of 0.36 to 0.65 and a p value below 0.0001, and an estimated 77% of patients remained progression-free at three years. The most common grade 3 or higher treatment-emergent adverse event was anemia, reported by 51% in the TALZENNA plus XTANDI group and 3% in the control group, and 5% of patients discontinued TALZENNA due to anemia.\n\n\"Today's approval of TALZENNA plus XTANDI builds on its established role as a standard-of-care option for men with advanced prostate cancer,\" said Aamir Malik, Executive Vice President, Chief U.S. Commercial Officer, Pfizer.\n\n## Pfizer's Recent Regulatory and Pipeline Moves\n\nPfizer is a global biopharmaceutical company that discovers, develops, and commercializes prescription medicines and vaccines across oncology, inflammation and immunology, vaccines, and internal medicine, according to akta.pro [company records](https://akta.pro/company-data). The same records show FY2025 revenue of $62.6 billion, a slight 1.6% decline year over year, and 96 pipeline projects as of May 5, 2026: 35 Phase 1, 25 Phase 2, 31 Phase 3, and 5 Registration.\n\nIn June 2026, Pfizer received FDA approval for IBRANCE in combination with trastuzumab and endocrine therapy for HR+/HER2+ metastatic breast cancer maintenance, the records show. The same records list a June 2026 leadership change, with CFO Dave Denton departing on August 15, 2026, and Cecile Guegan named Interim CFO effective August 16.\n\n## Earlier Pfizer Developments\n\nOn October 20, 2026, Pfizer terminated a phase 2 trial of its CXCR5 antibody PF-06835375 in primary immune thrombocytopenia, citing a business decision with no safety concerns, FierceBiotech reported. The trial involved 61 patients and began in 2022.\n\nOn October 22, 2026, FiercePharma reported that Pfizer is cutting jobs at three U.S. manufacturing plants, including about 150 at its Michigan facility and undisclosed numbers at two North Carolina sites, and an Italian plant. On October 20, 2026, EIN Presswire reported that Pfizer voluntarily recalled 15,815 bottles of Levoxyl thyroid medication over potency concerns, with the FDA classifying it as a Class II recall.\n\n## What Comes Next for the Combination\n\nAn application for TALZENNA plus XTANDI is under review by the European Medicines Agency, with additional global regulatory filings planned or underway, Pfizer said. The FDA reviewed the application under Project Orbis, an Oncology Center of Excellence initiative for concurrent submission and review of oncology drugs among international partners.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}